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Abstract
Background Radioresistance of thoracic radiotherapy is a
major bottleneck in the treatment of non-small cell lung cancer
(NSCLC). Until now, there have been no effective biomarkers
to predict the radiosensitivity.
Purposes Based on miRNA profile screened from NSCLC
cell lines with different radiosensitivity, this study was
conducted to explore the correlation between plasma
miRNAs and radiotherapy response in NSCLC patients, and
to identify biomarkers of the radiosensitivity in NSCLC.
Methods Differentially expressed genes were acquired from
time-series gene expression profiles of radioresistant H1299
and radiosensitive H460 lung cancer cells (GSE20549).
Potential miRNAs were screened from these differentially
expressed genes by combining bioinformatics with GO anal-
ysis, pathway analysis, and miRNA prediction. A clinical ob-
servational study was performed to explore the correlation
between candidate miRNAs and radiotherapy response.
Stage IIIa–IV NSCLC patients who received two to four cy-
cles of previous chemotherapy and underwent thoracic radio-
therapy alone were included. Total RNA was purified from
peripheral blood before radiotherapy, and plasma miRNAs
were detected by real-time PCR (qRT-PCR). Then, tumor re-
sponse, progression-free survival (PFS), and overall survival
(OS) were acquired. Four miRNAs significantly different be-
tween effective and ineffective groups were further analyzed
to obtain cutpoints from receiver operating characteristic
(ROC) curves and the predictive value of radiosensitivity.
Results Candidate miRNAs included 14 miRNAs screened
from radioresistant genes and five from radiosensitive genes.
From Jan., 2013 to Dec., 2014, 54 eligible patients were en-
rolled with a median follow-up of 15.3 months (range 4.6 to
31.4) by the deadline of Aug. 31, 2015. Totally, there were no
case of complete response (CR), 15 of partial response (PR),
35 of stable disease (SD), and 4 of progressive disease (PD).
Eight patients had no progression and 19 patients were still
alive. The median PFS and OS were 6.6 months (range 2.3 to
29.3) and 15.3 months (range 4.6 to 31.4), respectively. Four
miRNAs (hsa-miR-98-5p, hsa-miR-302e, hsa-miR-495-3p,
and hsa-miR-613) demonstrated a higher expression in effec-
tive group (CR+PR, 15 cases) than in ineffective group
(SD+PD, 39 cases). Based on each cutpoint, objective re-
sponse rate (ORR) was higher in miR-high group than in
miR-low group. No miRNA showed correlation with median
PFS or OS.
Conclusion Bioinformatical analysis and clinical verification
reveal the correlation between plasma miRNAs and radiosen-
sitivity in NSCLC patients. Plasma miRNAs represent novel
biomarkers to predict radiotherapy response clinically.
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Introduction
Lung cancer is the most common cancer worldwide with
a 5-year survival rate less than 20 % [1, 2]. Non-small
cell lung cancer (NSCLC) is the largest subgroup of lung
cancer, approximately 70 % of which is unresectable
stage III or IV disease. Thoracic radiotherapy has been
the main treatment for advanced NSCLC patients [3].
However, radical thoracic radiotherapy usually cannot
eradiate the tumor. Radioresistance is a major bottleneck in
the treatment of tumor and its relapse [4]. The local recurrence
rate in NSCLC is up to 60–70 % in 2 years after conventional
fractionated radiotherapy (CFRT) (60 Gy/30 F/6 W) [5, 6].
Therefore, it is very critical to enhance the radiosensitivity of
lung cancer so as to reduce the relapse.
The mechanism of radioresistance is very complicated, and
it may involve pathological type, tumor microenvironment,
radioresistant genes, DNA damage repair (DDR), tumor
heterogenicity, individual differences, etc. [7, 8]. However,
so far, no reliable biomarkers have been identified to stratify
patients into different subgroups of radiotherapy response [9].
Recent studies indicate that miRNAs, a class of short non-
coding RNAs, are involved in radioresistance [10–12]. As
we know, miRNAs regulate cell cycle, cell proliferation, apo-
ptosis, and tumor angiogenesis via targeting mRNA for deg-
radation or inhibition of translation [13–16]. Moreover,
miRNAs demonstrate a strong ability to regulate radiation
response and DDR [10–12, 17]. All the above findings show
that it is essential to obtain miRNAs associated with radiosen-
sitivity. Thus, we attempted to explore the role of plasma
miRNAs in predicting radiosensitivity in NSCLC.
In the current study, we screenedmiRNA profile associated
with radiation response by comprehensive bioinformatical
analysis of the time-series gene chips from irradiated
NSCLC cell lines in the Gene Expression Omnibus (GEO)
database. Then, we performed a clinical observational study
to explore the correlation between plasma miRNAs and radio-
therapy response in NSCLC patients. We also analyzed the
predictive sensitivity and specificity of single miRNA or
combined miRNAs. By doing this, we introduce a novel tech-
nology to predict radiosensitivity in NSCLC patients via
detecting plasma miRNAs.
Materials and methods
Screening miRNA profile via bioinformatics
We searched the GEO database for gene chips of radiotherapy
response in lung cancer and found GSE20549 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE20549) with
the time-series gene expression profiles of radioresistant
H1299 and radiosensitive H460 lung cancer cells in response
to 2 Gy of ionizing radiation (IR). Comprehensive bioinfor-
matics was then used to process the data, including GO anal-
ysis, pathway analysis, and miRNA prediction at home-made
platform. Then, miRNA-mRNA networks were built to screen
candidate miRNA profile associated with radiotherapy
response [Supplementary material, Fig. 1a, b].
Total RNA extraction from plasma
About 5 mL of non-coagulant blood was collected from every
eligible patient. Plasma was isolated by centrifuging at
3000 rpm for 10 min at 4 °C, and stored at −80 °C. Total
RNA extraction followed the manufacturer’s instruction of
mirVana™ PARIS™Kit (Ambion, USA). Briefly, chloroform
was added to 200 μL of plasma, which was mixed with 2×
denaturing solution and incubated on ice for 5 min. After
centrifuging and removing the aqueous (upper) phase,
100 % ethanol was added, mixed thoroughly, pipetted onto
the filter cartridge, and then centrifuged. After washing by
350 μL of wash solution three times, the filter was added with
100 μL of preheated (95 °C) nuclease-free water and centri-
fuged for 30 s to recover the RNA.
Real-time RT-PCR (qRT-PCR) assay
We followed the previous protocol for primer design and qRT-
PCR adopted by our institute [18]. Total RNA was reversely
transcribed into cDNAwith standard techniques (ABI, USA).
Synthetic cel-39 small RNA (Ribobio, China) was used as an
external control. The universal sense primer of miRNAs was
5′-GTGCAGGGTCCGAGGT-3′. Reverse transcription
primer and antisense primer for qRT-PCR are listed in
Supplementary Table S1. To enhance the efficacy of real-
time PCR, pre-amplification of miRNAs was carried out using
2×Taq PCR MasterMix (Qiagen, Germany) before real-time
PCR. The pre-amplication was carried out as follows.
Reaction system included 2 μL of cDNA, 1 μL of mixed
antisense primers, 1 μL of universal sense primer, 12.5 μL
of 2×Taq PCRMasterMix, and 8.5 μL of nuclease-free water.
Reaction condition was as follows: 94 °C for 3 min, 10 cycles
of 94 °C for 30 s, 60 °C for 30 s, 72 °C for 1 min, and 72 °C for
15 min before being stored at −20 °C. Then, real-time PCR of
cel-39 and miRNAs was performed using SYBR® Green
PCR Master Mix (ABI, USA) as previously reported [18].
All the qRT-PCR reactions were repeated no less than three
times.
Patients
NSCLC patients confirmed by histological or cytological di-
agnosis were enrolled in the Oncology Department, Xinqiao
Hospital, Third Military Medical University. TNM classifica-
tion followed the International Classification of Diseases for
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Oncology [19]. Inclusion criteria included unresectable stage
III or IV disease, two to four cycles of previous chemotherapy,
unfitness for concurrent radiochemotherapy, Eastern
Cooperative Oncology Group (ECOG) performance status
(PS) 0–2, and an age from 18 to 75 years. Moreover, all eli-
gible patients signed the informed consent form. Exclusion
criteria included anti-tumor therapy within 4 weeks, previous
thoracic radiotherapy and malfunction of vital organs. This
study has been approved by the Ethics Committee of Third
Military Medical University.
Study design and workflow
The clinical observation study was performed from Jan., 2013
to Dec., 2014 (Fig. 2a). Every eligible patient received thorac-
ic radiotherapy to the planning gross tumor volume (pGTV)
(60–66 Gy/30–33 F/6–7 W). About 5 mL of non-coagulant
blood was drawn before radiotherapy. Follow-up continued
every month during and after radiotherapy by Aug. 31,
2015. Tumor response was estimated by RECIST 1.1.
Median progression-free survival (PFS) and overall survival
(OS) were recorded. The objective response rate (ORR) was
defined as the proportion of patients with complete response
(CR) or partial response (PR). PFS was calculated during the
period from the first radiotherapy to disease progression. OS
was calculated during the period from the first radiotherapy to
death. Finally, the primary objective of ORR, secondary
objectives of PFS, OS and radiation pneumonia (RP), and
the exploring index of predictive sensitivity and specificity
were analyzed.
Statistical analysis
The expression of plasma miRNAs was compared by the
independent-sample t test based on homogeneity test. The
ORR comparison was analyzed by the standard chi-square
test. The PFS and OS were estimated using the Kaplan-
Meier method. Statistical analyses were performed with
SPSS 17.0 (SPSS Inc., Chicago, IL, USA) at P<0.05. The
cutpoints of miRNAs were obtained from receiver operating
characteristic (ROC) curves using MedCalc 15.10.
Results
Screening of candidate miRNA profile via bioinformatics
The GSE20549 discovered time-series gene expression pro-
files of radiotherapy reaction in NSCLC cell lines with 42
pieces of gene chips. A total of 12 samples were hybridized
to Affymetrix Human Gene 1.0 Array gene chips. We
screened differentially expressed genes associated with
radioresistance and radiosensitivity by Two Class Dif. Based
on the standards of gene significance level (P<0.05) and false
Fig. 1 Bioinformatics of miRNA associated with radiosensitivity in
NSCLC. a miRNA-gene-network (14 miRNAs associated with
radioresistant genes). b miRNA-gene-network (5 miRNAs associated
with radiosensitive genes). Red rectangles represent miRNAs, blue
circles represent gene ontology, and straight lines represent the
regulation between miRNAs and gene ontology
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discovery rate (FDR < 0.05), 118 radioresistant genes
and 1055 radiosensitive genes were primitively isolated
(Supplementary differentially expressed genes.xls).
GO analysis was performed on all the above differentially
expressed genes. After calculating the difference between
gene significance level (P< 0.05) and FDR (FDR<0.05),
GO analysis exhibited 107 kinds of functions and 35
genes in radioresistant group, and 42 kinds of functions
and 137 genes in radiosensitive group (Supplementary GO
analysis.xls).
Pathway analysis was performed on all the above differen-
tially expressed genes based on KEGG (Kyoto Encyclopedia
of Genes and Genomes). Fisher’s exact test and chi-square test
were used. After calculating the difference between gene
significance level (P<0.05) and FDR (FDR<0.05), pathway
analysis showed 5 kinds of functions and 10 genes in the
radioresistant group and 18 kinds of functions and 143 genes
in the radiosensitive group (Supplementary pathway
analysis.xls).
All the above differentially expressed genes from both GO
analysis and pathway analysis were analyzed using miRNA
prediction tools. With the criterion of correlation index
(R≥0.5), we acquired 23 radioresistant genes and 26 potential
miRNAs and 97 radiosensitive genes and 17 potential
miRNAs, which are listed in Supplementary Table S2. By
removing the intersecting miRNAs in both groups, two topol-
ogy maps of miRNA-mRNA networks demonstrated the 14
miRNAs associated with radioresistant genes (Fig. 1a), and
five miRNAs associated with radiosensitive genes (Fig. 1b),
respectively. Specifically, the 14 miRNAs associated with
radioresistant genes included hsa-miR-153-3p, hsa-miR-1-
3p, hsa-miR-613, hsa-miR-372-3p, hsa-miR-302e, hsa-miR-
495-3p, hsa-miR-206, hsa-miR-520a-3p, hsa-miR-328-3p,
hsa-miR-520b, hsa-miR-1297, hsa-miR-520d-3p, hsa-miR-
193a-3p and hsa-miR-520e, and the 5 miRNAs associated
with radiosensitive genes included hsa-let-7c-5p, hsa-miR-98-
5p, hsa-miR-203a-3p, hsa-miR-137, and hsa-miR-34c-5p.
Patient characteristics
Collectively, 312 NSCLC patients were selected, among
whom 96 met the inclusion criteria. However, 12 cases gave
up radiotherapy due to severe side effects, and the other 27
cases were excluded because they received chemotherapy or
targeted molecular therapy within the past 4 weeks; in addi-
tion, three cases had metastatic lung nodules. Eventually, the
data of the remaining 54 patients are illustrated in our
workflow (Fig. 2b).
All of the 54 patients (47 males and 7 females) with a
median age of 60 years (range 31–75 years), 37 cases
(68.5 %) were ever or current smokers. Seven patients were
in stage IIIa (13.0 %), 22 (40.7 %) in stage IIIb, and 25
(46.3 %) in stage IV. It should be specified that the seven
patients with stage IIIa disease did not undergo surgical resec-
tion because of the high risk of surgical intervention (Table 1).
Fig. 2 Study design and workflow. a Study design. b Flow chart of patient selection
11930 Tumor Biol. (2016) 37:11927–11936
Tumor response and miRNA difference
Waterfall map showed maximum tumor response in 54 pa-
tients (Fig. 3a). Totally, 54 eligible patients reached 0 CR,
15 PR, 35 SD, and 4 PD. Eight patients had no progression
and 19 patients were still alive. The median PFS and OS were
6.6 months (range 2.3 to 29.3) and 15.3 months (range 4.6 to
31.4), respectively. We divided all the eligible patients into
effective group (CR+PR, 15 cases) and ineffective group
(SD+PD, 39 cases). There was no baseline difference in pa-
tient characteristics between two groups in terms of age, sex,
histological type, disease stage, and smoking status (P>0.05,
Table 1). Among these 19 candidate miRNAs, four miRNAs
(hsa-miR-98-5p, hsa-miR-302e, hsa-miR-495-3p, and hsa-
miR-613) demonstrated a higher expression in effective group
than in ineffective group (P<0.05) (Fig. 3b).
Plasma miRNAs and ORR
Furthermore, ROC curves demonstrated the cutpoints of these
four miRNAs as follows: hsa-miR-98-5p >0.14 (P=0.0056),
hsa-miR-302e >214.65 (P=0.0035), hsa-miR-495-3p >16.92
(P<0.0001), and hsa-miR-613 >0.54 (P<0.0001) (Fig. 3c).
We divided the 54 eligible patients into miR-high and
miR-low groups based on the cutpoint criterion of each
miRNA to compare the difference of ORR. We validated
the significance of four above miRNAs in radiotherapy
response (Fig. 3d). The ORRs of miR-high and miR-low
groups were 63.6 vs. 18.6 % in hsa-miR-98-5p (P=0.000),
76.9 vs. 12.2 % in hsa-miR-302e (P=0.000), 41.2 vs. 5 % in
hsa-miR-495-3p (P=0.011), and 50.0 vs. 14.7 % in hsa-miR-
613 (P=0.003), respectively (Table 2).
Plasma miRNAs and PFS, OS, RP
The median follow-up was 15.3 months (range 4.6 to 31.4).
Eight patients had no progression and nineteen patients were
still alive. The median PFS and OS were 6.6 months (range
2.3 to 29.3) and 15.3 months (range 4.6 to 31.4), respectively.
Comparison of PFS and OS difference in miR-high and miR-
low groups of above miRNAs revealed that no miRNA was
associated with PFS or OS (P>0.05, Fig. 4).
RP of grades 1–4 occurred in 57.4 % of overall pa-
tients (31/54), in 60.0 % of patients in effective group
(9/15), and in 56.4 % in ineffective group (22/35). There
was no significant difference in RP between effective
and ineffective groups (P > 0.05, Table 1). And there
was no significant difference in RP between miR-high
and miR-low groups, either, in hsa-miR-98-5p (57.1 vs.
36.4 %), hsa-miR-302e (53.8 vs. 41.5 %), hsa-miR-495-3p
(44.1 vs. 45.0 %), and hsa-miR-613 (58.3 vs. 33.3 %), respec-
tively (P>0.05).
Sensitivity and specificity of plasma miRNAs
Moreover, we calculated the predictive sensitivity and speci-
ficity of plasma miRNAs in radiotherapy response. The sen-
sitivity and specificity ranged from 67 to 93 %, 49 to 90 %,









Median (range) 60 (31–75) 58.5 (31–71) 60.6 (38–75)
Sex, N (%) 0.688
Male 47 (87.0) 14 (93.3) 33 (84.6)
Female 7 (13.0) 1 (6.7) 6 (15.4)
Histological type, N (%)
SCC 32 (59.3) 9 (60.0) 23 (59.0) 0.945
Non-SCC 22 (40.7) 6 (40.0) 16 (41.0)
Disease stage, N (%) 0.997
IIIa 7 (13.0) 2 (13.3) 5 (12.8)
IIIb 22 (40.7) 6 (40.0) 16 (41.0)
IV 25 (46.3) 7 (46.7) 18 (46.2)
Smoking status, N (%) 0.884
Never 17 (31.5) 4 (26.7) 13 (33.3)
Ever or current 37 (68.5) 11 (73.3) 26 (66.7)
Radiation pneumonitis 0.811
Yes 31 (57.4) 9 (60.0) 22 (56.4)
No 23 (42.6) 6 (40.0) 17 (43.6)
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respectively, in single miRNA; from 67 to 80 %, 72 to 97 %,
respectively, in combination of two miRNAs; and from 60 to
67 %, 87 to 97 %, respectively, in combination of three
miRNAs. And the sensitivity and specificity reached 60 and
97 % in combination of four miRNAs, respectively. With the
addition of combination of miRNAs, the specificity increased
while the sensitivity decreased. The conclusive results are
listed in detail in Table 3.
Discussion
The morbidity and mortality of lung cancer remain high [20].
Radiotherapy is a key therapeutic strategy for lung cancer.
However, most of patients suffer from the radioresistance
which will decrease radiotherapy efficacy. Thus, it is urgent
to overcome tumor radioresistance and enhance tumor radio-
sensitivity. By far, radiotherapy efficacy is mainly improved in
Fig. 3 Tumor response and radiosensitivity prediction by plasma
miRNAs. a Waterfall map of maximum tumor response in 54 patients.
b Differentially expressed plasma miRNAs based on tumor response.
Four miRNAs have a significant difference (*P< 0.05). c Cutpoints in
receiver operating characteristic (ROC) curves of plasma miRNAs
(*P< 0.05). d Tumor response based on cutpoints of plasma miRNAs
(*P< 0.05, **P< 0.01)
Table 2 Correlation between Plasma miRNAs and tumor response
Tumor response hsa-miR-98-5p hsa-miR-302e hsa-miR-495-3p hsa-miR-613
miR-high
N= 21, n (%)
miR-low
N= 33, n (%)
miR-high
N= 13, n (%)
miR-low
N= 41, n (%)
miR-high
N= 34, n (%)
miR-low
N= 20, n (%)
miR-high
N= 24, n (%)
miR-low
N= 30, n (%)
CR 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
PR 12 (57.1) 3 (9.1) 10 (76.9) 5 (12.2) 14 (41.2) 1 (5.0) 12 (50.0) 3 (10.0)
SD 9 (42.9) 26 (78.8) 3 (23.1) 32 (78.0) 17 (50.0) 18 (90.0) 11 (45.8) 24 (80.0)
PD 0 (0) 4 (12.1) 0 (0) 4 (9.8) 3 (8.8) 1 (5.0) 1 (4.2) 3 (10.0)
ORR 12 (57.1) 3 (9.1) 10 (76.9) 5 (12.2) 14 (41.2) 1 (5.0) 12 (50.0) 3 (10.0)
P value 0.000 0.000 0.011 0.003
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two ways. On the one hand, high-end equipments and ad-
vanced technology are introduced, such as positron emission
computed tomography (PET-CT), stereotactic radiotherapy
(SBRT), and image-guide radiotherapy (IGRT). In spite of
this, the local control of lung cancer is still not optimistic
[21–23]. On the other hand, predictive biomarkers of
Fig. 4 PFS and OS comparison
based on miRNA level. Kaplan-
Meier analysis of PFS and OS
based on plasma miRNA level.
No miRNA is associated with
PFS or OS
Table 3 Sensitivity and
specificity of plasma miRNA
prediction
miRNAs Prediction by single or combination of miRNAs
hsa-miR-98-5p + − − − + − − + + − + + − + +
hsa-miR-302e − + − − − + − + − + + − + + +
hsa-miR-495-3p − − + − + + + − − − + + + − +
hsa-miR-613 − − − + − − + − + + − + + + +
Sensitivity (%) 80 67 93 80 80 67 80 67 80 60 67 67 60 60 60
Specificity (%) 77 92 49 69 85 97 72 95 87 95 97 87 97 97 97
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radiosensitivity are studied as a useful strategy to monitor
radiotherapy and optimize treatment plan in advance.
As known, miRNAs are a kind of small non-coding RNA
molecules of about 22 nucleotides in length [24]. They are
deemed to play a crucial role in the diagnosis, prognosis,
and recurrence of lung cancer [25–27]. A number of studies
have reported the potential clinical application of miRNAs in
lung cancer radiotherapy. Some miRNAs are used to enhance
anticancer therapy by regulating cell cycle, cell proliferation
and apoptosis, DNA damage repair, tumor angiogenesis, and
so on [28]. For example, miR-200c promoted radiosensitivity
by downregulating oxidative response genes and inhibiting
DNA repair in lung cancer [29]. Overexpression of miR-
449a effectively increased irradiation-induced DNA damage
and apoptosis, altered the cell cycle distribution and eventual-
ly led to sensitization of CL1-0 cell line to irradiation [30].
Upregulation of miR-138 enhanced radiosensitivity of lung
cancer cells by inhibiting SENP1 and increasing apoptosis
[31]. In addition, Let-7 and miR-25 have been proved to im-
prove radiosensitivity in human tumors including lung cancer
[9, 32]. Elevated evidence showed that circulating miRNAs
could be potential biomarkers for early diagnosis and progno-
sis prediction in lung cancer [33, 34]. And miR-21 was veri-
fied as a biomarker for ionizing radiation in breast cancer [35].
However, there is no report about the role of plasma miRNAs
in predicting radiosensitivity in NSCLC patients.
To our knowledge, the present research is the first one of its
kind to screen miRNA profile and explore the correlation
between plasma miRNAs and radiosensitivity in NSCLC pa-
tients. Four miRNAs (hsa-miR-98-5p, hsa-miR-302e, hsa-
miR-495-3p, and hsa-miR-613) displayed the ability as indica-
tors of radiosensitivity based on both tumor response criterion
and miRNA level criterion. As we know, miRNAs usually
downregulate target genes by inhibiting translation [12–15]. It
is supposed that miRNAs associated with radioresistant genes
may be radiosensitive candidates, and vice versa, miRNAs
associated with radioresensitive genes may be radioresistant
candidates. Actually, three miRNAs (hsa-miR-302e, hsa-miR-
495-3p, and hsa-miR-613) associated with radioresistant genes
demonstrated the predictive value. However, one miRNA (hsa-
miR-98-5p) associated with radiosensitive genes also exhibited
the function as an indicator of radiosensitivity. To our knowl-
edge, miRNA expression usually changes during the process of
disease progression and anti-tumor treatment. Possibly,
radioresistant miRNAs would be downregulated, and radiosen-
sitive miRNAs would be upregulated following the delivery of
radiation in effective group. Nevertheless, it is not a good
choice to predict the treatment effect by detecting the dynamic
status of miRNA level during the delivery of radiotherapy. In
current study, we aim to search for the biomarkers to predict the
radiotherapy response before the treatment. The changes in
miRNA after the radiotherapy are not our concern. And it is
unnecessary to distinguish the function of a predicted miRNA
before the radiotherapy. Thus, this study only reflects the
relationship between plasma miRNAs and tumor response to
radiotherapy. Future studies can be conducted to detect multi-
phase miRNA level during the radiotherapy and to explore the
underlying mechanism to validate our results.
Consistent with our research, several previous studies
showed that some above miRNAs were involved in the
radio- or chemosensitivity. For example, miR-302 was
inversely correlated with AKT1 and RAD52, two critical
regulators of radioresistance. And miR-302a sensitized
radioresistant breast cancer cells to radiotherapy in vitro and
in vivo [36]. Overexpression of miR-495 increased the
chemosensitivity of platinum-resistant lung adenocarcinoma
cells by inhibiting copper-transporting P-type adenosine
triphosphatase A (ATP7A), a gene of multi-drug resistance
[37]. These findings confirm that the miRNAs mentioned
above play an important role in radiotherapy reaction.
All eligible patients were strictly controlled to receive no
chemotherapy, targeted molecular therapy or other anti-tumor
therapy within 4 weeks before receiving radiotherapy. Our
results show that the above four miRNAs are correlated with
tumor response, but not PFS or OS, which could be caused by
complex factors in PFS and OS, such as subsequent treatment
and PS condition. According to Power and Precision v4, the
power of PFS and OS ranges from 0.129 to 0.446 and 0.171 to
0.407, respectively, based on a one-sided significance level of
0.1. This low power may bring a false negative conclusion.
Therefore, further prospective studies are needed, and a suit-
able sample size ought to be considered.
We also explored the predictive sensitivity and specificity
of plasmamiRNAs. Single miRNA displayed a relatively high
sensitivity and a low specificity, and combined miRNAs
showed a relatively low sensitivity and a high specificity.
This result implies that plasma miRNAs can stratify NSCLC
patients into radiosensitive and radioresistant subgroups. For
the radioresistant subgroup, comprehensive intervention
should be considered before radiotherapy, such as a higher
dose or a concurrent strategywith other anticancer therapy [9].
Conclusion
Our study provides the preliminary results that plasma
miRNAs represent novel biomarkers to predict radiotherapy
response in clinical settings. These findings lay the foundation
for further validating the regulatory mechanism of target
genes, GO and signal pathway in the radiosensitivity of
NSCLC. Our study also provides guidance for clinical treat-
ment. This study suggests that hsa-miR-98-5p, hsa-miR-302e,
hsa-miR-495-3p, and hsa-miR-613 in plasma can be used as
radiosensitivity indictors in NSCLC patients. Stage III multi-
center clinical trial and further studies on the underlying
mechanism are needed.
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